22.72
-0.6(-2.57%)
Currency In USD
Address
114 East 4th Avenue
Middletown, BC V5T 1G4
Canada
Phone
16046781388
Website
Sector
Healthcare
Industry
Biotechnology
Employees
299
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | 1.16M | 1962 |
| Leone D. Patterson | Executive VP and Chief Business & Financial Officer | 317,579 | 1962 |
| Paul Moore | Chief Scientific Officer | 757,501 | 1967 |
| Diana Papove | Senior Manager of Corporate Communications | 0 | N/A |
| Jeffrey Smith | Executive VP & Chief Medical Officer | 0 | 1959 |
| Lindsey Foulkes | Vice President of Corporate Development | 0 | N/A |
| Sabeen Mekan | Senior Vice President of Clinical Development | 0 | N/A |
| Daniel Dex | Senior Vice President, Corporate Secretary & General Counsel | 0 | N/A |
| John Fann | Senior Vice President of Process Sciences | 0 | N/A |
| Mark Hollywood | Executive Vice President and Head of Technical & Manufacturing Operations | 0 | 1969 |
| Scott Platshon | Acting Chief Investment Officer | 0 | 1991 |
| Laura O'Connor | Vice President of Human Resources & DEI | 0 | N/A |
| Shrinal Inamdar | Director of Investor Relations | 0 | N/A |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.